Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers Matthew R. Weir Invited Commentary Pages: 333 - 335
Evolving strategies for the use of combination therapy in hypertension Alan H. GradmanCelso Acevedo OriginalPaper Pages: 343 - 349
Managing the hypertensive patient with ischemic heart disease Clive Rosendorff OriginalPaper Pages: 350 - 357
Optimizing blood pressure control in the obese patient Tobias PischonArya M. Sharma OriginalPaper Pages: 358 - 362
Renal dysfunction as a cardiovascular risk factor Eberhard RitzRalf DikowLuis M. Ruilope OriginalPaper Pages: 365 - 368
Ambulatory blood pressure measurement in the renal patient Adrian CovicDavid J. A. Goldsmith OriginalPaper Pages: 369 - 376
Hypertensinogenic mechanism of the calcineurin inhibitors John J. Curtis OriginalPaper Pages: 377 - 380
Hypertension as a cardiovascular risk factor in end-stage renal failure Carmine ZoccaliFrancesca MallamaciGiovanni Tripepi OriginalPaper Pages: 381 - 386
Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy Hans-Henrik ParvingPeter Hovind OriginalPaper Pages: 387 - 393
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: Evidence for and against the combination in the treatment of hypertension and proteinuria Niels Holmark AndersenCarl Erik Mogensen OriginalPaper Pages: 394 - 402
Angiotensin II and progressive renal insufficiency Jens GaedekeNancy A. NobleWayne A. Border OriginalPaper Pages: 403 - 407